Zacks Investment Research upgraded shares of Innocoll Holdings PLC (NASDAQ:INNL) from a sell rating to a hold rating in a research note published on Tuesday morning.
According to Zacks, “Innocoll Holdings develops and manufactures pharmaceutical products and medical devices through its proprietary collagen-based technologies. The company’s product include CollaGUARD(Ex-US), CollatampG(R), Septocoll(R), RegenePro(R), Collieva(R), CollaCare(R), Collexa(R) and Zorpreva(TM). It operates primarily in Asia, Australia, Canada, Europe, Latin America, the Middle East and the United States. Innocoll AG, formerly known as Innocoll GmbH, is headquartered in Athlone, Ireland. “
Several other equities research analysts have also recently weighed in on INNL. Stifel Nicolaus cut Innocoll Holdings PLC from a buy rating to a hold rating and reduced their price objective for the stock from $9.00 to $2.00 in a research note on Friday, March 17th. JMP Securities raised Innocoll Holdings PLC to an outperform rating and set a $4.00 price objective on the stock in a research note on Wednesday, March 29th. Finally, FBR & Co reissued a hold rating on shares of Innocoll Holdings PLC in a research note on Thursday, April 6th. Four equities research analysts have rated the stock with a hold rating and one has given a buy rating to the stock. Innocoll Holdings PLC presently has a consensus rating of Hold and an average target price of $3.75.
Innocoll Holdings PLC (NASDAQ:INNL) opened at 2.13 on Tuesday. The stock has a 50 day moving average price of $1.89 and a 200-day moving average price of $1.78. Innocoll Holdings PLC has a 12-month low of $0.53 and a 12-month high of $12.94. The stock’s market capitalization is $63.36 million.
TRADEMARK VIOLATION WARNING: “Innocoll Holdings PLC (INNL) Raised to Hold at Zacks Investment Research” was reported by Watch List News and is owned by of Watch List News. If you are viewing this article on another domain, it was illegally copied and republished in violation of international copyright legislation. The correct version of this article can be accessed at http://www.watchlistnews.com/innocoll-holdings-plc-innl-raised-to-hold-at-zacks-investment-research/1275057.html.
An institutional investor recently raised its position in Innocoll Holdings PLC stock. Alyeska Investment Group L.P. raised its stake in shares of Innocoll Holdings PLC (NASDAQ:INNL) by 57.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 837,626 shares of the specialty pharmaceutical company’s stock after buying an additional 305,482 shares during the period. Alyeska Investment Group L.P. owned about 2.82% of Innocoll Holdings PLC worth $578,000 at the end of the most recent reporting period. Institutional investors own 42.88% of the company’s stock.
Innocoll Holdings PLC Company Profile
Innocoll Holdings Public Limited Company is a commercial-stage specialty pharmaceutical and medical device company with late-stage development programs. The Company operates through the segment of manufacture and sale of collagen-based pharmaceutical products. It utilizes collagen-based technology platform to develop its biodegradable and bioresorbable products and product candidates, which can be broken down by the body without the need for surgical removal or applied topically.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Innocoll Holdings PLC Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Innocoll Holdings PLC and related companies with Analyst Ratings Network’s FREE daily email newsletter.